

This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization

WHO Technical Report Series

933

THE SELECTION AND USE OF ESSENTIAL MEDICINES

Report of the WHO Expert Committee, 2005
(including the 14th Model List of Essential Medicines)



World Health Organization

Geneva 2006

WHO Library Cataloguing-in-Publication Data

WHO Expert Committee on the Selection and Use of Essential Medicines

(14th : 2005: Geneva, Switzerland)

The selection and use of essential medicines : report of the WHO Expert Committee, 2005 : (including the 14th model list of essential medicines).

(WHO technical report series ; 933)

1.Essential drugs — standards 2.Formularies — standards 3.Drug information services — organization and administration 4.Drug utilization 5. Pharmaceutical preparations — classification 6.Guidelines I.Title II.Title: 14th model list of essential medicines III.Series.

ISBN 92 4 120933 X
ISSN 0512-3054

(LC/NLM classification: QV 55)

© World Health Organization 2006

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications — whether for sale or for noncommercial distribution — should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization.

Typeset in China, Hong Kong Special Administrative Region

Contents

1. Introduction	1
2. Open session	2
3. Update on current activities on selection and rational use	3
3.1 Dissemination of the previous report of the Expert Committee (including the 13th Model List)	3
3.2 WHO Model Formulary and WHO Essential Medicines Library	4
3.3 Plans for further revisions of the Model List and <i>WHO model formulary</i>	4
3.4 Review of essential medicines for reproductive health	5
3.5 Review of the Interagency Emergency Health Kit 2005	5
3.6 Report of the WHO Advisory Committee on Safety of Medicinal Products	6
3.7 Update on current activities in the field of rational use of medicines	6
3.8 Report of the Critically Important Antibiotics for Human Health Meeting, Canberra, Australia, 15–17 February 2005	7
3.9 Update on the Priority Medicines Project	8
3.10 Collaboration with the International Society of Drug Bulletins	8
3.11 Discussion	8
4. Changes made in revising the Model List	9
4.1 Applications for deletions	9
4.1.1 Aminophylline and theophylline	9
4.1.2 Atropine	10
4.1.3 Calcium gluconate	10
4.1.4 Clonazepam	11
4.1.5 Codeine	11
4.1.6 Colchicine	12
4.1.7 Cromoglycic acid	12
4.1.8 Diethyltoluamide	13
4.1.9 Ergotamine	13
4.1.10 Ergometrine	14
4.1.11 Ether	14
4.1.12 Factors VIII and IX concentrates	15
4.1.13 Imipenem + cilastatin	16
4.1.14 Isoprenaline	17
4.1.15 Levofloxacin	17
4.1.16 Local anaesthetic, astringent or anti-inflammatory as antihaemorrhoidal medicines	18
4.1.17 Medroxyprogesterone acetate (depot injection 150mg/ml)	18
4.1.18 Medroxyprogesterone acetate (tablet 5mg)	19
4.1.19 Nalidixic acid	19
4.1.20 Niclosamide	20
4.1.21 Nifedipine	20
4.1.22 Oxamniquine	21

4.1.23	Polygeline	21
4.1.24	Procainamide	22
4.1.25	Pyrantel	22
4.1.26	Quinidine	23
4.1.27	Salbutamol	23
4.1.28	Silver nitrate eye solution	23
4.1.29	Sodium fluoride	24
4.1.30	Spectinomycin	24
4.1.31	Sun protection agents	25
4.1.32	Thioacetazone + isoniazid	25
4.1.33	Triclabendazole	27
4.2	Applications for additions	27
4.2.1	Caffeine citrate	27
4.2.2	Cefixime	28
4.2.3	Clotrimazole	28
4.2.4	Combination injectable contraceptives	29
4.2.5	Emtricitabine	29
4.2.6	Emtricitabine + tenofovir fixed-dose combination	30
4.2.7	Etonogestrel-releasing implant	30
4.2.8	Ibuprofen paediatric suspension	31
4.2.9	Levonorgestrel-releasing implant	32
4.2.10	Levonorgestrel-releasing IUD	32
4.2.11	Methadone and buprenorphine	33
4.2.12	Methoxyflurane	34
4.2.13	Miltefosine	35
4.2.14	Nifedipine	35
4.2.15	Mifepristone with misoprostol	36
4.2.16	Misoprostol, low dose	37
4.2.17	Nifedipine	38
4.2.18	Tenofovir	38
4.2.19	Zinc sulfate	39
4.3	Other changes	40
4.3.1	Alcuronium and vecuronium	40
4.3.2	Antiretroviral medicines	40
4.3.3	Ceftriaxone 1 g injection	41
4.3.4	Immunoglobulin, human normal	41
4.3.5	Labetalol	42
4.3.6	Prostaglandins for postpartum haemorrhage	43
5.	Reviews of sections of the Model List	43
5.1	Beta-lactam medicines	43
5.2	General anaesthetics and oxygen	44
5.3	Muscle relaxants	44
5.4	Ophthalmological preparations	44
6.	Rare diseases	44
7.	Future priorities	45
7.1	Summary of recommendations — additions, changes and deletions to the Model List	45
7.2	Methodological issues	48
7.3	Rational medicine use	48

References	49
Annex 1	
The 14th WHO Model List of Essential Medicines	54
Annex 2	
The Anatomical Therapeutic Chemical (ATC) classification system	93
Alphabetical list of essential medicines (with ATC classification code numbers)	112

WHO Expert Committee on the Selection and Use of Essential Medicines

Geneva, 7–11 March 2005

Members

- Dr T.I. Bhutta, International Paediatric Association, Lahore, Pakistan
- Dr P.M. de Buschiazzi, Department of Pharmacology, School of Medicine, University of La Plata, La Plata, Argentina
- Dr A. Helali, Director, Centre National de Pharmacovigilance et Matéiovigilance, Ministère de la Santé et de la Population, Algiers, Algeria
- Dr S. Hill, Department of Clinical Pharmacology, University of Newcastle, New South Wales, Australia (*Rapporteur*)
- Dr J.-R. Laporte, Department of Pharmacology and Therapeutics, Fundacio Institut Català de Farmacologia, Universitat Autònoma de Barcelona, Barcelona, Spain (*Chairman*)
- Mr D. Mehta, Executive Editor, British National Formulary, Royal Pharmaceutical Society of Great Britain, London, England
- Dr E.M.A. Ombaka, Coordinator, Ecumenical Pharmaceutical Network, Nairobi, Kenya
- Dr Marcus M. Reidenberg, Chief, Division of Clinical Pharmacology, Weill Medical College of Cornell University, New York, NY, USA
- Dr S. Suryawati, Department of Clinical Pharmacology, Centre for Clinical Pharmacology and Drug Policy Studies, Gadjah Mada University, Yogyakarta, Indonesia
- Dr L. Wannmacher, Department of Clinical Pharmacology, School of Medicine, University of Passo Fundo, Passo Fundo, Rio Grande do Sul, Brazil
- Dr L. Ziganshina, Kazan State Medical Academy, Department of Clinical Pharmacology and Pharmacotherapy, Kazan, Russian Federation

Representatives of other organizations*

Joint United Nations Programme on HIV/AIDS

Dr Julian Fleet, Senior Adviser, Care and Public Policy, UNAIDS, Geneva, Switzerland

United Nations Children's Fund (UNICEF)

Ms T. Huong Ha, Pharmaceuticals and Micronutrients, Supply Division UNICEF, Copenhagen, Denmark

United Nations Population Fund (UNFPA)

Dr G. Walker, Director, Country Services Team for Eastern Europe and Central Asia, Bratislava, Slovakia

Dr Vincent Fauveau, Maison Internationale de l'environnement, Chatelaine, Geneva, Switzerland

* Unable to attend: the World Bank and the WHO Collaborating Centre for International Drug Monitoring.

Secretariat

- Dr L.A. Bero, University of California at San Francisco, San Francisco, CA, USA
(*Temporary Adviser*)
- Dr J. Collier, International Society of Drug Bulletins, Medicines Policy Unit, Pharmacology and Clinical Pharmacology, St George's Hospital Medical School, London, England (*Temporary Adviser*)
- Dr L.G. Cuervo-Amore, Clinical Evidence, BMA House, London, England (*Temporary Adviser*)
- Dr A. Gray, Department of Experimental and Clinical Pharmacology, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Congella, South Africa (*Temporary Adviser*)
- Dr R. Gray, Medical Officer, Policy, Access and Rational Use, Department of Medicines Policy and Standards, WHO, Geneva, Switzerland
- Dr U. Gupta, Delhi Society for Promotion of Rational Use Of Drugs, National Institute of Immunology, New Delhi, India (*Temporary Adviser*)
- Dr H.V. Hogerzeil, Director, Department of Medicines Policy and Standards, WHO, Geneva, Switzerland (*Secretary*)
- Dr R.O. Laing, Medical Officer, Policy Access and Rational Use, Department of Medicines Policy and Standards, WHO, Geneva, Switzerland
- Dr V.K. Lepakhin, Assistant Director-General, Health Technology and Pharmaceuticals (HTP Cluster), WHO, Geneva, Switzerland
- Dr Y. Li, Chinese Cochrane Centre, West China Hospital, Sichuan University, Chengdu, People's Republic of China (*Temporary Adviser*)
- Dr A.G. Miranda, HIV-TB Care and Treatment Team, Global AIDS Program, National Centers for HIV, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA (*Temporary Adviser*)
- Dr G. Mignot, la revue Prescrire, Paris, France (*Temporary Adviser*)
- Ms W. Yoongthong, Senior Pharmacist, Food and Drug Administration, Bangkok, Thailand
- Dr Ogori Taylor, Yaba, Lagos, Nigeria

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_29833

